589 related articles for article (PubMed ID: 26775592)
21. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
Rusthoven CG; Yeh N; Gaspar LE
Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.
Abbas G; Danish A; Krasna MJ
Surg Oncol Clin N Am; 2016 Jul; 25(3):553-66. PubMed ID: 27261915
[TBL] [Abstract][Full Text] [Related]
23. [Extracranial stereotactic radiotherapy for early-stage non-small cell lung cancer and oligometastases].
Riesterer O
Praxis (Bern 1994); 2013 Oct; 102(21):1309-16. PubMed ID: 24129299
[TBL] [Abstract][Full Text] [Related]
24. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
Niazi T; Elakshar S; Stroian G
Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiation therapy for metastases to the kidney in patients with non-small cell lung cancer: a new treatment paradigm for durable palliation.
Verma V; Simone CB
Ann Palliat Med; 2017 Apr; 6(2):96-103. PubMed ID: 28480719
[TBL] [Abstract][Full Text] [Related]
26. Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.
Stephens SJ; Moravan MJ; Salama JK
J Oncol Pract; 2018 Jan; 14(1):23-31. PubMed ID: 29324212
[TBL] [Abstract][Full Text] [Related]
27. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
Shultz DB; Diehn M; Loo BW
Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
[TBL] [Abstract][Full Text] [Related]
28. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
[TBL] [Abstract][Full Text] [Related]
29. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
31. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer.
Yano T; Okamoto T; Haro A; Fukuyama S; Yoshida T; Kohno M; Maehara Y
Lung Cancer; 2013 Dec; 82(3):431-5. PubMed ID: 24113550
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer.
Nakagawa T; Negoro Y; Matsuoka T; Okumura N; Dodo Y
Respir Investig; 2014 Jul; 52(4):221-6. PubMed ID: 24998368
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
34. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
35. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
36. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
Hamaji M; Chen F; Matsuo Y; Kawaguchi A; Morita S; Ueki N; Sonobe M; Nagata Y; Hiraoka M; Date H
Ann Thorac Surg; 2015 Apr; 99(4):1122-9. PubMed ID: 25661580
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
[TBL] [Abstract][Full Text] [Related]
38. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V; Park HS; Decker RH
Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
[TBL] [Abstract][Full Text] [Related]
39. [Stereotactic body radiotherapy for malignant nodules in the lung].
Nestle U; Guckenberger M
Zentralbl Chir; 2013 Oct; 138 Suppl 1():S25-31. PubMed ID: 24150852
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of oligometastatic or oligoprogression cancer].
Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
